Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (9895)	1/5/2007 4:21:48 PM
From: scaram(o)uche	Respond to of 10280

>> Doesn't seem to be possible << Well, of course it is. A metabolite could retain activity at serotonin receptors and lose it at H1. Otherwise, isn't this "fine tuning" just finding an anti-histamine with a best possible half-life, adding any quality of sleep issues that SEPR was trying to add to lunesta via ACAD's molecules (if that's possible on top of an anti-histamine?)? Activity at 2a, and NO detectable activity at 2b?